Xeltis, a Swiss-Dutch medical device company, announced that it has secured €15M quasi-equity financing from the European Investment Bank (EIB).
The financing is being made available under the European Guarantee Fund (EGF), a part of the €540B EU rescue package in response to the COVID-19 pandemic.
“In terms of medical technology innovations, what Xeltis is doing almost sounds like science fiction, yet it is already here,” says EIB Vice-President Kris Peeters.
“I think Europe can be proud that it is a breeding ground for such cutting-edge technology, which has the potential to significantly impact medical care in a number of fields. I am proud that, with help of the European Guarantee Fund, we can get behind Xeltis to help them accelerate their way out of this difficult global phase,” he added.